CHEST: American College of Chest Physicians Annual Meeting

A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.

Clinicians at CHEST 2026 say costs and outcomes are shaped well beyond the ICU, from surgical choices to discharge planning and end-of-life talks.

Samantha Pettigrew, MD, explains blood clot risk factors, treatment, and return to play in the wake of the news of Jalen Hurts season-ending diagnosis.

Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.

EMR inboxes and insurance peer-to-peer calls are pulling clinicians away from patients, a growing concern reflected across CHEST 2026.

A COPD discharge checklist and navigator improved readmissions without lengthening hospital stays or increasing emergency department revisits.

Early goals-of-care talks, ethics consults, and upstream planning can help ICU teams deliver care that matches what patients actually want.

ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.

At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.

Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.

Charge nurse–led multidisciplinary rounds caught ICU lines and catheters due for removal that academic teaching rounds often missed, said Pooja Roy, MD.

Limited access to care means safety-net ICUs see advanced disease and poorer outcomes, while bias and social media add new challenges to care.

Pulmonologists play a key role in comprehensive biomarker testing, helping more patients with lung cancer access precise targeted therapies.

Speakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.

On the opening day of CHEST 2026, the organization's flagship journal highlights a trio of key papers with practice-changing results for COPD.

Selected presentations from “Reframing COPD: Phenotypes, Outcomes, Therapeutics, and the Future of Care Delivery,” a session on the opening day of CHEST 2026.

New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.

Top content from this year's CHEST meeting in Chicago focused on bronchiectasis treatment, particularly the newly FDA-approved brensocatib (Brinspuri; Insmed).

Brensocatib improves lung structure and reduces exacerbations in non-cystic fibrosis bronchiectasis with or without COPD, according to posters presented at this year's CHEST meeting.

Experts at CHEST 2025 highlight rising costs, insurance complexity, and workforce shortages as major barriers to health care access in the US.

Vaccine awareness, safety, and addressing misinformation are all important to improve adherence and public health outcomes, said Kristina Crothers, MD.

Panels held throughout the conference emphasized both how far the specialization has come but also how far it has yet to go.

Dedicated COPD respiratory therapists can improve inhaler use, ensure adherence, and bridge care transitions, explained Megan Dulohery Scrodin, MD.

Meta-analyses presented at the CHEST 2025 Annual Meeting find that combinations that include amivantamab and nivolumab improved overall and progression-free survival in non–small cell lung cancer (NSCLC).

Digitized behavioral cough suppression therapy is a safe, highly effective, and accessible alternative to drugs for chronic cough, said Laurie Slovarp, PhD.

The efficacy of GLP-1 inhibitors in weight loss has introduced them as a means of also addressing obstructive sleep apnea in sleep medicine.

A session held during the CHEST 2025 Annual Meeting focused on the North American guidelines for treating bronchiectasis.

CT scans can play a role not just in diagnosing but also in monitoring non–cystic fibrosis bronchiectasis management, explained James D. Chalmers, MD.

Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation strategies, said Sara Assaf, MD.

Counseling patients with obstructive sleep apnea on using GLP-1s effectively prior to starting treatment can help ensure adherence, said Matthew Biszewski, PharmD.